Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819190 | 1.00 | PPARG (0.47) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL24740963 | 0.93 | LMNA (0.51) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL17819186 | 0.92 | PPARG (0.48) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL17819189 | 0.92 | PPARG (0.48) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL24741250 | 0.92 | PPARG (0.47) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL23036303 | 0.90 | PPARG (0.45) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL23036301 | 0.90 | PPARG (0.45) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL17819251 | 0.90 | PPARG (0.46) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL17819249 | 0.90 | PPARG (0.46) | PPARGRXRAHPGDALDH1A1KDM4E | |
| SCHEMBL23036532 | 0.90 | PPARG (0.46) | PPARGRXRAHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | claimed |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2022-08-09 | — | — | US | claimed |
| US-20200223815-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | claimed |
| EP-3666268-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | claimed |
| US-9862698-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, INC. (US) | 2018-01-09 | — | — | US | claimed |
| EP-3233794-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100542-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20160168113-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2016-06-16 | — | — | US | claimed |
| US-20160168108-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. | 2016-06-16 | — | — | US | claimed |
| US-12479813-B2 | Method of therapeutically treating cancer | ADT PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-20160168108-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168113-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2016-06-16 | — | — | US | disclosed |
| US-20160168113-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2016-06-16 | — | — | US | disclosed |
| US-20160168108-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-20160168113-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | BOYD, MICHAEL R. | 2016-06-16 | — | — | US | disclosed |
| US-20160168108-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, INC. | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885HPGD 1377/4885 |
| US-20200223815-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885HPGD 1377/4885 |
| US-12479813-B2 | Method of therapeutically treating cancer | RECQL, RDX, RNASE1 | PPARG 1690/4885RXRA 40/4885HPGD 1587/4885 |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885HPGD 1377/4885 |
| US-20160168113-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885HPGD 1377/4885 |
| US-20160168108-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | PPARG 1654/4885RXRA 62/4885HPGD 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.